# advanced solid tumors FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/advanced-solid-tumors

> 2 upcoming FDA catalysts in advanced solid tumors: LUMYKRAS™ (sotorasib, AMGN) on July 2028 (primary completion); LUMYKRAS™ (sotorasib, AMGN) on Jul to Oct 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2023 | [CLN-617 trial start](https://sec-api.dev/pdufa/cln-617) | CGEM | advanced solid tumors | completed | "In December 2023, we dosed the first patient in the ongoing Phase 1 clinical trial of CLN-617 in patients with advanced solid tumors." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1789972/000095017025028346/cgem-20241231.htm)) |
| Jan 2024 | [FT825 trial start](https://sec-api.dev/pdufa/ft825) | FATE | advanced solid tumors | completed | "In January 2024, we initiated a multi-center, Phase 1 clinical trial of FT825 for the treatment of advanced solid tumors (NCT06241456) alongside our collaborator Ono Pharmaceutical (see "Our Partnership with Ono Pharmaceutical")." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1434316/000119312526073699/fate-20251231.htm)) |
| Jul 2024 | [Dinger trial start](https://sec-api.dev/pdufa/dinger) | SDGR | advanced solid tumors | completed | "In July 2024, we initiated dosing in a Phase 1 clinical trial of SGR-3515 in patients with advanced solid tumors." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1490978/000149097826000076/sdgr-20260930.htm)) |
| Jul 2025 | [BNT324 trial start](https://sec-api.dev/pdufa/bnt324) | BNTX | advanced solid tumors | completed | "-In July 2025, the first patient was dosed in a Phase 2 clinical trial (NCT06953089) evaluating BNT324/DB-1311 in combination with pumitamig or with TROP2 ADC candidate BNT325/DB-1305 in patients with advanced solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000065/bnt_2025q3ex99x1quarterlyr.htm)) |
| Jun 2026 | [IM-1617 trial start](https://sec-api.dev/pdufa/im-1617) | IMNM | advanced solid tumors | completed | "IM-1617: In June 2026, the first patient was dosed in the Phase 1, first-in-human trial evaluating IM-1617 in patients with advanced solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm-ex99_1.htm)) |
| Q3 2026 | [ARV-6723 trial start](https://sec-api.dev/pdufa/arv-6723) | ARVN | advanced solid tumors | scheduled | "Arvinas plans to initiate a Phase 1 clinical trial of ARV-6723 in patients with advanced solid tumors in Q3 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828026052139/q22026earningsrelease.htm)) |
| late 2026 | [IM-1340 trial start](https://sec-api.dev/pdufa/im-1340) | IMNM | advanced solid tumors | scheduled | "IM-1340, a potential first-in-class ADC, received investigational new drug, or IND, clearance in September 2026, and we plan to initiate a Phase 1 trial in patients with advanced solid tumors by the end of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)) |
| July 2028 | [LUMYKRAS™ (sotorasib) primary completion](https://sec-api.dev/pdufa/sotorasib) | AMGN | Advanced Solid Tumors | scheduled | "NCT07172919 (A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-01 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07172919)) |
| Jul to Oct 2028 | [LUMYKRAS™ (sotorasib) topline data readout](https://sec-api.dev/pdufa/sotorasib) | AMGN | Advanced Solid Tumors | scheduled | "NCT07172919 (A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-01 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07172919)) |

## Drugs

- [CLN-617](https://sec-api.dev/pdufa/cln-617) (CGEM)
- [FT825](https://sec-api.dev/pdufa/ft825) (FATE)
- [Dinger](https://sec-api.dev/pdufa/dinger) (SDGR)
- [BNT324](https://sec-api.dev/pdufa/bnt324) (BNTX)
- [IM-1617](https://sec-api.dev/pdufa/im-1617) (IMNM)
- [ARV-6723](https://sec-api.dev/pdufa/arv-6723) (ARVN)
- [IM-1340](https://sec-api.dev/pdufa/im-1340) (IMNM)
- [LUMYKRAS™ (sotorasib)](https://sec-api.dev/pdufa/sotorasib) (AMGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/advanced-solid-tumors.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "advanced solid tumors FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/advanced-solid-tumors

```bibtex
@misc{secapidev_indications_advanced_solid_tumors_20261116,
  title        = {advanced solid tumors FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/advanced-solid-tumors}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_advanced_solid_tumors_20261116","title":"advanced solid tumors FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/advanced-solid-tumors","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
